SG10201913567QA - Btla fusion protein agonists and uses thereof - Google Patents
Btla fusion protein agonists and uses thereofInfo
- Publication number
- SG10201913567QA SG10201913567QA SG10201913567QA SG10201913567QA SG10201913567QA SG 10201913567Q A SG10201913567Q A SG 10201913567QA SG 10201913567Q A SG10201913567Q A SG 10201913567QA SG 10201913567Q A SG10201913567Q A SG 10201913567QA SG 10201913567Q A SG10201913567Q A SG 10201913567QA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion protein
- protein agonists
- btla fusion
- btla
- agonists
- Prior art date
Links
- 101150025010 Btla gene Proteins 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 229940076376 protein agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187105P | 2015-06-30 | 2015-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913567QA true SG10201913567QA (en) | 2020-02-27 |
Family
ID=57609132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913567QA SG10201913567QA (en) | 2015-06-30 | 2016-06-29 | Btla fusion protein agonists and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (3) | US10961297B2 (pt) |
EP (1) | EP3317297A4 (pt) |
JP (4) | JP7116285B2 (pt) |
KR (2) | KR102669985B1 (pt) |
CN (2) | CN108026159B9 (pt) |
AU (3) | AU2016286108B2 (pt) |
BR (1) | BR112017028316A2 (pt) |
CA (1) | CA2990885A1 (pt) |
EA (1) | EA201890171A1 (pt) |
IL (2) | IL256383B2 (pt) |
MX (1) | MX2018000073A (pt) |
SG (1) | SG10201913567QA (pt) |
WO (1) | WO2017004213A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201705116SA (en) | 2015-01-20 | 2017-08-30 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
WO2017004213A1 (en) | 2015-06-30 | 2017-01-05 | Sanford-Burnham Medical Research Institute | Btla fusion protein agonists and uses thereof |
GB201820554D0 (en) | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6291207B1 (en) * | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
US8546541B2 (en) | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
WO2007001459A2 (en) | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
AU2003243781A1 (en) | 2002-06-24 | 2004-01-06 | Amniotech, Inc. | Amniotic membrane mediated delivery of bioactive molecules |
US7153950B2 (en) | 2002-10-25 | 2006-12-26 | Genentech, Inc. | Nucleic acids encoding an immune related polypeptide |
CN101421298A (zh) * | 2004-11-12 | 2009-04-29 | 健泰科生物技术公司 | 用于治疗免疫相关疾病的新组合物和方法 |
US8349320B2 (en) * | 2004-12-09 | 2013-01-08 | La Jolla Institute For Allergy And Immunology | Compositions and methods for modulating responses mediated or associated with BTLA activity |
EP1833848A2 (en) | 2004-12-09 | 2007-09-19 | Lajolla Institute for Allergy and Immunology | Novel tnf receptor regulatory domain |
WO2010006071A1 (en) * | 2008-07-08 | 2010-01-14 | La Jolla Institute For Allergy And Immunology | Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use |
JPWO2007010692A1 (ja) | 2005-07-19 | 2009-01-29 | 独立行政法人科学技術振興機構 | Hvem及びbtlaを標的とした炎症性腸疾患治療用医薬組成物及び治療方法 |
CN101578296A (zh) | 2006-11-15 | 2009-11-11 | 梅达雷克斯公司 | 结合btla的人类单克隆抗体及使用方法 |
US8318662B2 (en) | 2009-03-16 | 2012-11-27 | Korea Institute Of Radiological & Medical Sciences | Protein increasing cell infectivity of herpes simplex virus and use thereof |
US8303952B2 (en) | 2009-06-08 | 2012-11-06 | Washington University | Methods for inducing in vivo tolerance |
JP5898617B2 (ja) | 2009-07-31 | 2016-04-06 | メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. | Btlaに対する完全ヒト抗体 |
CA2854809A1 (en) * | 2011-11-15 | 2013-05-23 | Sanford-Burnham Medical Research Institute | Compositions and methods for treating autoimmune and inflammatory disorders |
CA2923314A1 (en) | 2013-09-05 | 2015-03-12 | Sanford-Burnham Medical Research Institute | Modulation of .gamma..delta.t cells |
EP3277727B1 (en) | 2015-04-02 | 2021-11-03 | Memorial Sloan Kettering Cancer Center | Tnfrsf14/ hvem proteins and methods of use thereof |
EP3288587A4 (en) | 2015-04-29 | 2018-09-12 | Sanford-Burnham Medical Research Institute | Modulation of immune response using btla agonist antibodies |
WO2017004213A1 (en) | 2015-06-30 | 2017-01-05 | Sanford-Burnham Medical Research Institute | Btla fusion protein agonists and uses thereof |
CA3013333A1 (en) | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
EP3470424A4 (en) | 2016-06-08 | 2020-03-04 | Shanghai Jiaotong University School of Medicine | SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY |
CN109414426A (zh) | 2016-07-05 | 2019-03-01 | 瑞华药业集团 | 使用精氨酸耗竭剂的组合癌症免疫疗法 |
US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
JP2020521759A (ja) | 2017-05-26 | 2020-07-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ |
WO2019080898A1 (en) | 2017-10-27 | 2019-05-02 | Shanghai Yao Yuan Biotechnology Co., Ltd. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE RESPONSE BY ACTIVATION OF PROTEIN KINASE ALPHA 1 |
WO2019094559A2 (en) | 2017-11-09 | 2019-05-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
BR112020023844A2 (pt) | 2018-05-25 | 2021-04-13 | Alector Llc | Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica |
EP3810189A1 (en) | 2018-06-19 | 2021-04-28 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
CN112384532A (zh) | 2018-06-29 | 2021-02-19 | 艾利妥 | 抗SIRP-β1抗体及其使用方法 |
US20210340268A1 (en) | 2018-08-20 | 2021-11-04 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
US20220049010A1 (en) | 2018-09-14 | 2022-02-17 | Université de Lausanne | Methods for modulating regulatory t cells and inhibiting tumor growth |
US20220002423A1 (en) | 2018-11-15 | 2022-01-06 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
-
2016
- 2016-06-29 WO PCT/US2016/040108 patent/WO2017004213A1/en active Application Filing
- 2016-06-29 EP EP16818691.4A patent/EP3317297A4/en active Pending
- 2016-06-29 JP JP2017568205A patent/JP7116285B2/ja active Active
- 2016-06-29 SG SG10201913567QA patent/SG10201913567QA/en unknown
- 2016-06-29 US US15/737,259 patent/US10961297B2/en active Active
- 2016-06-29 IL IL256383A patent/IL256383B2/en unknown
- 2016-06-29 CN CN201680049768.5A patent/CN108026159B9/zh active Active
- 2016-06-29 KR KR1020187002960A patent/KR102669985B1/ko active IP Right Grant
- 2016-06-29 IL IL297395A patent/IL297395B2/en unknown
- 2016-06-29 KR KR1020247017225A patent/KR20240110000A/ko active Search and Examination
- 2016-06-29 CA CA2990885A patent/CA2990885A1/en active Pending
- 2016-06-29 CN CN202210348320.0A patent/CN114853903A/zh active Pending
- 2016-06-29 MX MX2018000073A patent/MX2018000073A/es unknown
- 2016-06-29 BR BR112017028316A patent/BR112017028316A2/pt active Search and Examination
- 2016-06-29 AU AU2016286108A patent/AU2016286108B2/en active Active
- 2016-06-29 EA EA201890171A patent/EA201890171A1/ru unknown
-
2021
- 2021-03-01 US US17/188,912 patent/US11939367B2/en active Active
- 2021-05-17 JP JP2021083133A patent/JP2021113240A/ja active Pending
- 2021-06-08 AU AU2021203768A patent/AU2021203768B2/en active Active
-
2022
- 2022-07-20 JP JP2022115473A patent/JP2022141840A/ja active Pending
-
2023
- 2023-04-14 AU AU2023202302A patent/AU2023202302A1/en not_active Abandoned
- 2023-12-13 JP JP2023210069A patent/JP2024019529A/ja active Pending
-
2024
- 2024-02-15 US US18/442,988 patent/US20240247047A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250044A1 (zh) | Gitrl融合蛋白及其用途 | |
HRP20190028T1 (hr) | Interleukin-2 fuzijski proteini i njihove primjene | |
HK1244019A1 (zh) | 融合蛋白 | |
HK1252958A1 (zh) | 單臂i型和ii型受體融合蛋白和其用途 | |
GB201509413D0 (en) | Fusion protein | |
GB201509062D0 (en) | OX40L fusion proteins and uses thereof | |
HK1246315A1 (zh) | 細胞因子融合蛋白 | |
IL297395B1 (en) | btla fusion protein agonists and uses thereof | |
GB2570063B (en) | Fusion protein and applications thereof | |
GB201504691D0 (en) | Fusion protein | |
ZA202003845B (en) | Fusion proteins | |
HK1257937A1 (zh) | 融合蛋白 | |
GB201602850D0 (en) | Fusion proteins | |
EP3649159C0 (en) | FUSION PROTEIN | |
GB201712792D0 (en) | Fusion protein | |
HK1251456A1 (zh) | 免疫球蛋白融合蛋白及其用途 |